AbbVie Inc (BUE:ABBV)
ARS 20300 -2850 (-12.31%) Market Cap: 308.31 Tn Enterprise Value: 372.12 Tn PE Ratio: 60.57 PB Ratio: 51.09 GF Score: 68/100

Abbvie Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 02:30PM GMT
Release Date Price: ARS4040.5
Christopher Joseph Raymond;Robert A. Michael
Piper Sandler & Co., Research Division - MD & Senior Research Analyst;AbbVie Inc

Okay. We're going to go ahead and get started. Thanks, everybody, for being here for day 3 of the Piper Sandler Healthcare Conference. My name is Chris Raymond. I'm one of the biotech analysts here at Piper Sandler. Very pleased to have with us our next company, which needs no introduction is AbbVie, of course, I have with me the Vice Chairman and President, to my left, Rob Michael, Jeff Stewart, EVP and Chief Commercial Officer; Tom Hudson, who is the Chief Scientific Officer; and Scott Reents, CFO.

So we have a full complement of management here for our talk. So normally, we ask companies to give a 2- or 3-minute overview on the company. I don't think we need to sort of go into that. So maybe we'll just dive into Q&A.

And this is a fireside chat format meant to be very informal. If anybody has any questions, please raise your hand. I'll make sure it gets asked and answered effectively. So thanks again for being here.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot